Compare Pfizer Inc (PFE) vs Ulta Beauty Inc (ULTA) Price & Performance

Pfizer (PFE) trades at $24.75, down 1.2% on the day, with a neutral technical outlook. The company maintains strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $0.75 beating expectations of $0.722. Pfizer demonstrates robust profitability with a 73.51% gross margin and 11.83% net income margin, though revenue has moderated from pandemic peaks. Recent news highlights the company's focus on AI drug discovery and pipeline development.

Pfizer presents a value opportunity trading below analyst consensus target of $28.25, with 38% of analysts rating it Buy. The stock offers a solid dividend yield with recent $0.43 payments. Key risks include patent expirations and revenue normalization post-COVID, while catalysts include obesity and oncology pipeline developments in 2026.

ULTA Beauty trades at $489.47, up 2.06% with a bullish technical signal despite mixed moving averages. The company maintains strong profitability with 39.33% gross margins and 47.45% ROE, though net margins have declined from 12.17% in 2023 to 10.63% in 2025. Recent Q1 2026 earnings beat expectations at $7.74 EPS versus $6.89 expected, while Q4 2025 missed. Analyst consensus remains strongly positive with 26 buy ratings and a $618.29 price target, representing 26% upside potential.

ULTA presents a compelling growth story with international expansion and digital engagement driving long-term potential. However, investors face risks from margin compression, competitive pressures in beauty retail, and volatile cash flow patterns. The stock's current valuation at 18.29x P/E appears reasonable given growth prospects, but requires monitoring of consumer spending trends and execution on strategic initiatives.